A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This is a phase II, randomized, placebo-controlled, double-blind study to evaluate the
efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's
disease. An optional 96-week open-label extension period will be available to participants
who complete the double-blind treatment period and who, in the judgment of the investigator,
would potentially benefit from open-label Semorinemab treatment.